Abstract 1270P
Background
This study aims to evaluate the feasibility of utilizing digital droplet polymerase chain reaction (ddPCR) for the detection of specific driver gene mutations (EGFR L858R/19del or KRAS G12C/D) in ctDNA for MRD monitoring in resected NSCLC patients with the mentioned mutations.
Methods
Plasma samples were collected every 3 or 6 months to detect EGFR L858R/19del or KRAS G12 C/D mutations from patients with resected NSCLC, using a single point assay. A binary logistic analysis was performed to assess the impact of these factors on MRD outcomes.
Results
Our study included 300 patients with resected NSCLC, with a median age of 62 years. Among them, 54% of patients had the EGFR L858R mutation, 34% had EGFR 19del, 10% had KRAS mutation, and the remaining 2% exhibited multiple mutations. The majority of participants were diagnosed with Stage IA NSCLC (71%), followed by 14% with Stage IB, 7% with Stage II, and 7% with Stage III. In terms of histological subtype, invasive adenocarcinoma accounted for 85% of cases, while 10% had Adenocarcinoma In Situ/Minimally Invasive Adenocarcinoma (AIS/MIA). The longest follow-up period was 39 months, with a median follow-up time of 33 months. A total of 607 blood samples were collected, with 10% of samples from AIS/MIA and 17% of samples from invasive adenocarcinoma showing MRD positivity. Among different gene mutations, the positive rates for MRD were 15% for EGFR L858R, 19% for EGFR 19del, and 18% for KRAS. In our binary logistic analysis, patients who received adjuvant therapy had a higher likelihood of MRD negativity (odds ratio: 0.50 [95% CI: 0.27, 0.95], p < 0.05). A higher TNM stage was associated with a higher likelihood of MRD positivity (OR: 2.13 [95% CI: 1.51, 2.99], p < 0.001).
Conclusions
Our findings indicate that ddPCR is a feasible option for detecting MRD in resected NSCLC with common driver genes, its accuracy was supported by the results of relevant subgroup analysis. Considering the elevated prevalence of EGFR mutations in the Asian population, our personalized tumor-informed approach targeting EGFR may offer a cost-effective solution. Nevertheless, additional data are necessary to substantiate its efficacy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Center for Respiratory Medicine; The First Affiliated Hospital of Guangzhou Medical University.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1288P - Neoadjuvant therapy with anti-PD-1/PD-L1 plus platinum-base chemotherapy for resectable stage II-III non-small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials
Presenter: Maria Dacoregio
Session: Poster session 04
1289TiP - LANTERN study: A multi-omics digital human avatar for integrating precision medicine into clinical practice for lung cancer patients
Presenter: Emilio Bria
Session: Poster session 04
1294P - A final analysis of a phase II study of durvalumab immediately after completion of chemoradiotherapy in unresectable stage III non–small-cell lung cancer: TORG1937 (DATE study)
Presenter: Tetsuro Kondo
Session: Poster session 04
1296P - Neoadjuvant camrelizumab and apatinib in patients with resectable non-small-cell lung cancer: One-year update from a phase II trial
Presenter: Wei Guo
Session: Poster session 04
1297P - An open-label, prospective phase II study of tislelizumab in combination with chidamide as consolidation therapy in locally advanced, unresectable, stage III NSCLC
Presenter: Yi Hu
Session: Poster session 04
1298P - Chemotherapy with concurrent proton vs. photon radiotherapy in stage III NSCLC: Effects on hematological toxicity and immune therapy
Presenter: Francesco Cortiula
Session: Poster session 04
1299P - The role of radiotherapy in extensive-stage small cell lung cancer after durvalumab-based immunochemotherapy: A retrospective study
Presenter: Lingjuan Chen
Session: Poster session 04
1300P - Treatment and clinical outcome in recurrent/refractory locally advanced NSCLC following chemoradiotherapy and consolidative durvalumab
Presenter: Georg Evers
Session: Poster session 04